peptides for FAQ

Peptides are fragile molecules. Improper storage (temperatures above 8°C for reconstituted solutions) or contaminated bacteriostatic water causes protein denaturation. The peptide loses its three-dimensional structure and becomes biologically inactive. There's no home test for potency. Visual inspection only catches gross contamination (cloudiness, particulates), not loss of bioactivity. Purchasing from suppliers that provide third-party purity verification and proper storage guidance is non-negotiable. At Real Peptides, every batch undergoes amino acid sequencing and HPLC analysis to verify exact peptide structure and purity before shipping. This isn't standard across the industry.

Inspect every shipment immediately upon arrival and document storage conditions throughout transit. Lyophilized peptides tolerate brief ambient temperature exposure (24–48 hours at 15–25°C) without significant degradation, but extended exposure above 25°C or any exposure above 30°C likely compromises peptide integrity. Real Peptides ships all temperature-sensitive compounds with gel ice packs in insulated packaging designed to maintain 2–8°C for 48 hours under typical shipping conditions. If you receive a shipment with melted ice packs or warm peptide vials, contact the supplier immediately for replacement rather than proceeding with potentially degraded material. Running an entire study with compromised peptide produces unreliable data. The cost of replacement vials is trivial compared to wasted research time and animal use.

Switch to lipolytic peptides like AOD9604 or growth hormone secretagogues like CJC-1295/Ipamorelin, which target visceral fat through adrenergic receptor activation rather than gastric mechanisms. GI side effects—nausea, vomiting, diarrhea—occur in 30–45% of patients during GLP-1 dose titration because these receptors are highly expressed in gastric and intestinal tissue; the slower gastric emptying that contributes to satiety also triggers nausea. AOD9604 stimulates hormone-sensitive lipase in adipocytes without affecting GI motility, producing fat loss without the gastric side effects. Clinical trials showed no significant difference in GI adverse events between AOD9604 and placebo, making it a viable alternative for patients who cannot tolerate GLP-1 therapy.

Reconstitute peptides in bacteriostatic water containing 0.9% benzyl alcohol, which maintains sterility and prevents bacterial contamination across 28 days of repeated needle entry. Standard sterile water lacks preservatives and supports bacterial growth after the first puncture. Store all reconstituted peptides at 2–8°C between doses, never at room temperature, and use insulin syringes to minimize dead space that wastes solution. For protocols extending beyond 28 days, order peptides in multiple small vials rather than one large vial to avoid stability loss. A 5 mg vial reconstituted fresh every four weeks outperforms a 20 mg vial stored for 12 weeks.

Kisspeptin-10 stimulates endogenous LH and FSH release without suppressing the hypothalamic-pituitary axis, meaning it does not cause testicular atrophy or spermatogenic shutdown the way exogenous testosterone does. This makes kisspeptin-10 the only hormonal intervention that can restore testosterone levels while preserving or even enhancing fertility. Exogenous testosterone replacement would suppress FSH and halt spermatogenesis within 8–12 weeks, making it unsuitable for men planning conception.

TGF-β1 elevation is a hallmark of chronic mold illness and represents a distinct immunological pattern from acute cytokine storms. VIP is still first-line because it modulates the regulatory T-cell axis that controls TGF-β1 production, but expect slower response times. 12–16 weeks rather than 8–10. LL-37 is less useful here because TGF-β1 elevation isn't driven by bacterial LPS or secondary infection. Thymosin Alpha-1 remains valuable because TGF-β1 suppresses T-cell proliferation, and restoring T-cell function helps break the cycle. Consider pairing VIP with Thymosin Alpha-1 at standard doses and reassess TGF-β1 at week 12.

Use BPC-157 or TB-500 for acute injuries. Ligament tears, tendon strains, post-surgical repair. Both peptides accelerate the initial phases of tissue healing by increasing cell migration and collagen deposition at injury sites. For chronic osteoarthritis where cartilage has thinned over years, growth hormone secretagogues (Ipamorelin, CJC-1295) provide a permissive environment for cartilage maintenance by sustaining IGF-1 elevation. Acute injuries show response within 2–4 weeks; chronic cartilage support requires 8–16 weeks minimum because chondrocyte metabolic rate is exceptionally slow.

VIP or Thymosin Alpha-1. Both address the immune dysregulation that drives most symptoms. If your primary symptoms are brain fog, fatigue, and exercise intolerance, start with Thymosin Alpha-1 because it targets T-cell and NK cell function, which affect energy and neurological clarity. If your primary symptoms are respiratory issues, gut dysfunction, or you have documented cytokine elevations, start with VIP because it directly modulates the inflammatory cascade. BPC-157 is powerful for gut healing but won't address immune dysfunction upstream. LL-37 is a secondary add-on, not a foundational intervention.

Combination protocols may be appropriate. Kisspeptin-10 to restore testosterone production and PT-141 to address central arousal deficits. The two peptides act on distinct pathways and do not compete or interfere mechanistically. Clinical trials have not formally evaluated this combination, but the pharmacological rationale is sound: normalize hormonal support first (kisspeptin-10 administered daily for 2–4 weeks to restore baseline testosterone), then address residual arousal or performance anxiety with PT-141 as needed before sexual activity.

No. Peptides recalibrate immune and neurological systems, but they can't override ongoing mycotoxin exposure. Start with remediation or relocation and binder therapy first. VIP and Thymosin Alpha-1 modulate cytokine production, but if you're inhaling trichothecenes or ochratoxin A daily, the antigenic load overwhelms the recalibration effect. Anecdotally, patients who begin peptide therapy without addressing the source see initial symptom improvement that plateaus within 3–4 weeks as the immune system re-enters chronic activation. Remediate first, bind second, recalibrate third.

AOD-9604 and MOTS-c are ideal because neither affects insulin or glucose metabolism. AOD-9604 acts exclusively on adipose tissue via beta-3 adrenergic receptors, and MOTS-c actually improves insulin sensitivity by activating AMPK and increasing glucose uptake in skeletal muscle. Avoid IGF-1 LR3 in this context. It can cause hypoglycemia in insulin-resistant individuals due to direct insulin-like effects on glucose uptake. GH secretagogues (CJC-1295, Ipamorelin, MK-677) are generally safe but should be monitored. GH is mildly insulin-antagonistic, meaning it can raise fasting glucose slightly in predisposed individuals.

Discard it. Peptides are proteins. Temperature excursions above 8°C cause irreversible denaturation that neither visual inspection nor home potency testing can detect. Lyophilized peptides tolerate short-term ambient temperatures (up to 25°C for 48 hours), but reconstituted solutions must remain refrigerated. If a vial was left at room temperature for more than 4 hours, assume complete loss of activity. The financial cost of replacing a compromised vial is lower than the research cost of using inactive peptide and drawing false conclusions about efficacy.

Increase dietary protein to 2.0–2.2 g/kg body weight daily and verify leucine content reaches 2.5–3.0 g per meal. Growth hormone and IGF-1 elevation create the hormonal environment for muscle protein synthesis, but without adequate amino acid substrate and resistance training stimulus, anabolic signaling goes unused. Research published in the Journal of Nutrition found that older adults require 40% higher per-meal protein doses than younger adults to achieve equivalent mTOR activation. GH secretagogues amplify this requirement rather than eliminate it.

Deploy a test battery covering spatial memory (Morris water maze, radial arm maze), recognition memory (novel object recognition), working memory (T-maze alternation), and executive function (attentional set-shifting) rather than relying on a single outcome measure. Different peptides enhance different cognitive domains: Cerebrolysin improves global cognition scores but shows strongest effects on attention and processing speed; Dihexa produces pronounced spatial memory enhancement but minimal effects on recognition memory; P21 selectively improves contextual memory consolidation; Semax enhances working memory and cognitive flexibility. Testing only spatial memory when studying Semax will underestimate its true cognitive effects. Select outcome measures matched to each compound's primary mechanism and affected brain regions.

Elevated C-reactive protein, ESR, or pro-inflammatory cytokines (TNF-alpha, IL-6) six months post-antibiotic suggest immune dysregulation, not active infection. KPV 500–1000mcg daily addresses NF-κB-driven inflammation, particularly if gut symptoms (bloating, irregular bowel movements) persist—gut barrier dysfunction perpetuates systemic inflammation through endotoxin translocation. Combine with VIP 100–200mcg intranasally twice daily if neurological symptoms (brain fog, memory issues, mood changes) dominate the clinical picture—VIP crosses the blood-brain barrier and reduces neuroinflammation through macrophage M2 polarization.

Yes. And this is where peptides offer the most value. Chronic mold illness isn't ongoing poisoning; it's a self-perpetuating immune and neurological state triggered by past exposure. Even when mycotoxins are long cleared, the cytokine cascade, T-cell suppression, and mitochondrial dysfunction persist. VIP, Thymosin Alpha-1, and BPC-157 address these residual dysfunctions directly. Clinical observation suggests patients 2–5 years post-exposure often respond better to peptides than those still in the acute phase, because the confounding variable of active toxin load is removed. Expect 8–16 weeks to see measurable change in energy, cognition, and immune markers.

Increase the lipolytic stimulus by adding a metabolic modulator like AOD-9604 or MOTS-c. GH secretagogues elevate GH and IGF-1, but if you're in a caloric surplus or consuming high insulin-spiking meals around dosing windows, the anabolic signal dominates and fat oxidation is suppressed. GH stimulates lipolysis only in a low-insulin state. If insulin is elevated, hormone-sensitive lipase (the enzyme that breaks down triglycerides) is inhibited regardless of GH levels. The solution is either tighter dietary control (fasted cardio post-injection, carbohydrate timing away from GH pulses) or the addition of a peptide that bypasses insulin signaling entirely, like AOD-9604.

Intranasal bioavailability depends on mucosal health, sinus inflammation, and administration technique. Subcutaneous injection bypasses first-pass metabolism and mucosal barriers entirely, producing more consistent plasma concentrations. Particularly relevant for peptides like Semax and Selank. For researchers prioritising reproducibility, subcutaneous administration at 200–400 mcg per day produces tighter dose-response curves than intranasal protocols, though convenience favors the latter in human studies.

Thymosin Alpha-1 acts systemically on T-cell populations rather than directly on gut epithelium. Its effects on intestinal inflammation are mediated through immune modulation in gut-associated lymphoid tissue (GALT). Measurable changes may appear in systemic cytokine profiles or immune cell populations before histological improvements in mucosal tissue. If the study design expects direct epithelial repair, a compound targeting tight junctions or mucosal angiogenesis like BPC-157 may be more appropriate.

This is the expected outcome based on current evidence. Sarcopenia reflects chronic hormonal deficiency, not acute illness. Removing peptide support returns subjects to their baseline anabolic state within weeks. The STEP Extension trial model (used in obesity research) applies here: peptides restore a physiological state that returns when the intervention stops. Long-term peptide protocols require careful monitoring of IGF-1 levels, fasting glucose, and markers of tissue proliferation, but multi-year administration appears feasible in research settings based on MK-677 safety data extending to 24 months.